Toggle navigation
About
About us
Management Team
Board of Directors
Advisory Board
R&D
Immuno-oncology
Technology
Collaborations
Publications
Posters
Clinical program
Partnering
Investors
Overview
The share
Shareholder information
Nomination committee
Largest shareholders
Financial calendar
Reports & Presentations
Financial Reports
Presentations
Information Document
Events
Analyst coverage
IR Contact
National Prospectus 2024
News
Press releases & other news
Subscribe
Contact
post@lytixbiopharma.com
News
news
Press releases & other news
Subscribe
Apr 27, 2016
New LTX-315 article published in Cell Death and Differentiation
Title: The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade
Authors: T Yamazaki, JM Pitt, M Vétizou, A Marabelle, C Flores, Ø Rekdal, G Kroemer and L Zitvogel
This preclinical study further provides strong rationale for combining LTX-315 with checkpoint inhibitor anti CTLA4.
Read the article
Back